Page 31 - Collaborative Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response Researchers reporting on findings from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial in the UK are recommending that any therapeutic use of REGEN-COV may be best restricted to individuals without detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The RECVORY Collaborative Group says that among patients hospitalized with coronavirus disease 2019 (COVID-19), REGEN-COV reduced 28-day mortality by about one-fifth in those who were seronegativ...

Radiology Today newsmagazine reaches 40,000 radiology professionals nationwide on a monthly basis, covering areas such as Radiology Management, Bone Densitometry, Mammography, MRI, PACS, CT, Sonography, Nuclear Medicine, Radiation Oncology, Radiation Therapy, contrast agents, and more!

What have we learned to help battle future pandemics?

原标题：他带着梦的种子去了远方5月22日的湖南长沙，细雨凄迷。13时07分，“杂交水稻之父”、“共和国勋章”获得者、中国工程院院士袁隆平因病医治无效，在长沙与世长辞，享年91岁。举国哀悼。当天下午，千里之外的重庆市，西南大学附近花店的鲜花、

AstraZeneca: ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSO - (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER 1 AstraZeneca, NHS England and NICE have reached an agreement to enable early access to osimertinib for patients with this type of cancer, while NICE undertakes its appraisal. Patients with early-stage lung cancer are treated with the intention of cure; however, many relapse because treatment is limited to surgery and adjuvant chemotherapy. 2 Unprecedented clinical trial data show that o...